Prevention strategies for herpes zoster and post-herpetic neuralgia

J Clin Virol. 2010 May;48 Suppl 1(Suppl 1):S14-9. doi: 10.1016/S1386-6532(10)70004-4.

Abstract

Impairment of varicella zoster virus (VZV)-specific cell-mediated immunity, including impairment due to immunosenescence, is associated with an increased risk of developing herpes zoster (HZ), whereas levels of anti-VZV antibodies do not correlate with HZ risk. This crucial role of VZV-specific cell-mediated immunity suggests that boosting these responses by vaccination will be an effective strategy for reducing the burden of HZ. Other strategies focus on preventing the major complication of HZ--post-herpetic neuralgia. These strategies include pre-emptive treatment with drugs such as tricyclic antidepressants, anticonvulsants and analgesics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adult
  • Aged
  • Analgesics / therapeutic use
  • Anticonvulsants / therapeutic use
  • Antidepressive Agents, Tricyclic / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Herpes Zoster / complications
  • Herpes Zoster / immunology
  • Herpes Zoster / prevention & control*
  • Herpes Zoster Vaccine / administration & dosage*
  • Herpes Zoster Vaccine / immunology
  • Herpesvirus 3, Human / immunology*
  • Humans
  • Immunity, Cellular / immunology
  • Incidence
  • Middle Aged
  • Neuralgia, Postherpetic / drug therapy
  • Neuralgia, Postherpetic / immunology
  • Neuralgia, Postherpetic / prevention & control*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Vaccination

Substances

  • Analgesics
  • Anticonvulsants
  • Antidepressive Agents, Tricyclic
  • Antiviral Agents
  • Herpes Zoster Vaccine